Science

Combining Forces Creates Improved Anticancer Therapeutic

A scientist pushes a small gray button on a red metal box, activating a pump that shoots clear fluids from two syringes into a small compartment just a few square centimeters in size. From there, the mixture is forced through a thin tube into a thumb-sized glass vial, where it pools with a few small bubbles.

That scientist, Caleb Anderson, Ph.D., a postdoctoral fellow at NCI Frederick’s Chemical Biology Laboratory, was hired to solve a problem, and this machine and its contents represent the solution he has spent months designing, calibrating, and testing. The mixture contains tens of thousands of nanoparticles of a developmental novel therapeutic agent targeting mesothelioma, an aggressive form of cancer that affects the surface tissue lining various organs, such as the lungs.

Echoes from the Past: Frederick Made It Possible to Implement the First Blood Test for HIV

On April 9, 1984, a special package from Bethesda arrived at Building 560 on the Frederick Cancer Research Facility campus. In an unusual move, it came not by courier but by scientist, who carried it directly to a biosafety level 3 laboratory, at the time one of FCRF’s few facilities for working with highly dangerous biological entities. Exposure to the box’s contents meant likelihood of a protracted death. Julian Bess Jr. remembers when Larry Arthur, Ph.D., brought that box containing two sealed flasks of HIV-infected cells into their laboratory.

NCI-60 HTS384: NCI Cancer Therapeutic Screen Enters New, High-throughput Era

Robot R, part of NCI Frederick’s new automated apparatus for screening potential cancer therapeutics, uses its arm to meticulously fill the wells of a 384-well plate with droplets of human tumor cell cultures smaller than a raindrop. Robot L stands at the ready on the other side of the apparatus, awaiting its own instructions. Laboratory staff members work nearby, but after they load the apparatus with the supplies it needs, the robotic system carries on independently.

Clinical Monitoring Research Program to Support Clinical Study Exploring Alternative to Cervical Cancer Screening

A new U.S. clinical trial will evaluate whether an at-home, self-collection technique to screen for cervical cancer is as accurate and effective as a Pap smear test done in a healthcare clinic. The Clinical Monitoring Research Program Directorate at the Frederick National Laboratory for Cancer Research will coordinate the National Cancer Institute study to be conducted at 25 sites.

New CRISPR Screening Platform Could Drive Development of Next-Generation Drugs

Scientists at the Frederick National Laboratory for Cancer Research and their National Cancer Institute colleagues have developed a method that enhances the capacity to identify interactions between proteins and molecules that are critical to drug targeting. The study, reported in Science Advances, includes libraries to aid other researchers.

An Inspiring New Patent Wall Recognizing Meaningful Contributions

The Frederick National Laboratory for Cancer Research has a new installation: a wall featuring 34 plaques highlighting patents granted to FNL researchers in recognition of their inventions and the breakthrough work being done at the laboratory. The “Innovations in Research” wall represents the mission of FNL staff to address some of the most urgent challenges in the biomedical sciences.

Start Your Engines: Pandemic Lockdown Contributed to Team’s Discovery of Bacterial Motor Function

The lockdowns during 2020, the first year of the COVID-19 pandemic, temporarily paused most laboratory work, but they didn’t stop science from moving forward. Many scientists, including those comprising what’s now NCI’s Center for Structural Biology, seized the opportunity while out of the lab to revisit previously collected data. Those efforts are paying off.

Enhanced Antibody-Drug Conjugate Eradicates Large Breast Cancer Tumors in Experimental Models

In cancer therapeutics, targeted therapies are a rapidly developing field of interest. These include antibody-drug conjugates (ADCs), compounds that carry small-molecule anticancer drugs to specific antigens on tumors, directly killing tumor cells. Though the first ADC approved by the U.S. Food and Drug Administration (FDA) was brought to the clinic in 2000, it was later voluntarily removed due to high toxicity. Since then, more precise technologies have improved generations of ADCs, and there are currently 12 ADCs that are FDA-approved for clinical use. However, most available ADCs offer limited improvement and can still be toxic.

But a study conducted by researchers in the National Cancer Institute’s Center for Cancer Research and published in Cell Reports in December 2023 highlights a new ADC—carefully engineered, screened, and purified—that can eradicate large tumors in animal models at a dose per body weight that humans can tolerate, showing that ADCs can be improved and made less toxic. Clinical trials with humans will be needed to prove efficacy.

Cancer Research’s Newest Key Player—Artificial Intelligence

Visualizing protein structures in three dimensions instead of two has given scientists new insights into biological processes, and now artificial intelligence is adding the capacity to predict molecular behaviors that could potentially be borne out in laboratory studies. For Kylie Walters, Ph.D., a structural biologist with the NCI Center for Cancer Research in Frederick, artificial intelligence, or AI, has revolutionized the way her laboratory works.